Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Jacqueline Shea
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedVaccineFor |
gptkb:COVID-19
|
| gptkbp:focusesOn |
gptkb:cancer
infectious diseases immunotherapy DNA medicines |
| gptkbp:founded |
1979
|
| gptkbp:founder |
David B. Weiner
|
| gptkbp:headquartersLocation |
gptkb:Plymouth_Meeting,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Inovio Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
INO-4800
VGX-3100 |
| gptkbp:numberOfEmployees |
approximately 250
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockSymbol |
gptkb:NASDAQ
INO |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.inovio.com/
|
| gptkbp:bfsParent |
gptkb:WuXi_Biologics
|
| gptkbp:bfsLayer |
7
|